A jury found Elizabeth Holmes guilty of conspiring to defraud investors in failed thoroughbred testing start-up Theranos, delivering a victory to federal prosecutors in one of Silicon Valley’s most high-profile criminal fraud cases.
The jurors moreover convicted Holmes of three counts of wire fraud and conspiracy to commit wire fraud, while finding her not guilty on four remoter counts. They were deadlocked on three remaining charges. Holmes can request versus the verdict in state appeals court.
Jurors read out their visualization pursuit a dramatic day of deliberations at a federal courthouse in San Jose, California. Earlier, Judge Edward Davila had instructed the jury to protract their deliberations without they said they could not reach a unanimous verdict on all of the charges.
Holmes expressed little emotion as the verdict was read and left the courtroom with her lawyers without transiently hugging her partner and parents, equal to US wire reports. She had pleaded not guilty to the charges, which each delivering up to 20 years in prison.
The trial had engrossed tech industry watchers and fuelled a debate over the limits of Silicon Valley’s start-up culture at a time when venture wanted is pouring in at a record pace.
The verdict is the culmination of a nearly two decade-long saga that started in 2003, when Holmes, now 37, founded Theranos without dropping out of Stanford University. At its zenith, the visitor was valued at $9bn and she became a media darling who was profiled in multiple magazine imbricate stories.
But Theranos ended up stuff the subject a thundercrack of hair-trigger media reports, most notably by former Wall Street Journal journalist John Carreyrou, whose reporting in 2015 sparked spare scrutiny of the company.
A slew of regulatory investigations followed, sending the visitor into a tailspin that resulted in its break-up in 2018.
Holmes had personal Theranos’s novel technology could perform a wide range of tests using just a few drops of blood, though the visitor in the main relied on commercially misogynist machines.
The trial largely focused on whether Holmes intended to defraud investors in her company.
Prosecutors presented reams of documentary vestige and testimony from 29 witnesses, who detailed problems at Theranos’s laboratories and its evasive communications with investors.
The vestige provided the most detailed worth of how Theranos operated, revealing multiple instances in which Holmes appeared to promote misleading information.
Holmes admitted to placing the logos of pharmaceutical groups including Pfizer on Theranos documents she sent to investors, plane though they had not endorsed the company’s technology.
“She chose fraud over merchantry failure,” prosecutor Jeff Schenk said during latter arguments. “She chose to be dishonest. This nomination was not only callous, it was criminal.”
The defence team had tried to tint Holmes as an hostage entrepreneur who failed to deliver on promises to transform the thoroughbred testing industry. They moreover attempted to shift vituperation to others at Theranos, including Ramesh Balwani, who oversaw its finances as its president and senior operating officer.
Testifying in her own defence, Holmes accused Balwani, with whom she had a romantic relationship, of mental and sexual abuse, allegations his shyster has previously denied. Balwani will squatter similar fraud charges in a separate trial expected to uncork in February.
“Elizabeth Holmes was towers a merchantry and not a criminal enterprise,” Kevin Downey, her shyster at Williams & Connolly, said during latter arguments.